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Tumour cells expressing P-glycoprotein (P-gp) display resistance
to a wide range of chemically and structurally unrelated
chemotherapeutic drugs (reviewed by (Gottesman and Pastan,
1988). P-gp is localized to the plasma membrane and utilizes the
energy of ATP hydrolysis to efflux drugs from cells, thereby main-
taining their intracellular concentrations below cytotoxic levels. In
humans, the drug-resistance P-gp is encoded by a single gene
(MDR1), but in the mouse and other rodents the equivalent gene is
duplicated (mdr1a and mdr1b) (Gros et al, 1986; Devault and
Gros, 1990). The mouse P-gps are both 1276 amino acids in length
but have different apparent molecular weights (160 kDa and
180 kDa for P-gp1a and P-gp1b respectively), due to non-equiva-
lent glycosylation. The two murine proteins share 84% amino acid
identity, although the linker region which contains several sites for
phosphorylation by protein kinase C (PKC) is the least conserved
region between the two isoforms (Devault and Gros, 1990).
Despite their high level of sequence identity, the complementary
patterns of tissue-specific expression suggest that the two rodent
isoforms may perform distinct functions (Croop et al, 1989).
P-gp1a is expressed at high levels in the intestine, liver and testis,
and also in the lung and brain where it is thought to contribute to
the blood–brain barrier (Schinkel et al, 1994). In contrast, P-gp1b
is expressed in tissues associated with steroid biosynthesis and
distribution, such as the adrenal gland and ovary, and is induced
specifically in the uterus during pregnancy (Arceci et al, 1988;
Trezise et al, 1992). The steroid hormone progesterone increases
during pregnancy, and the mdr1b gene, but not the mdr1a gene, is
regulated by a progesterone response element in its promoter
(Piekarz et al, 1993). Direct evidence that the P-gp1b isoform can
transport steroids comes from the observation that disruption of
the  mdr1b gene in mouse adrenal cells is associated with
decreased adrenocorticotropic hormone-stimulated steroid secre-
tion (Altuvia et al, 1993). Taken together, these observations have
given rise to the suggestion that the P-gp1b isoform is involved in
the translocation of steroids such as progesterone.
A direct interaction of several steroid hormones with P-gp from
a variety of tissues and sources has been demonstrated in vivo.
More specifically, progesterone inhibits vinblastine binding and
azidopine photolabelling of both of the mouse P-gp isoforms in
vitro (Yang et al, 1990), showing that both isoforms are capable of
interacting with steroids. However, if the distinct tissue-specific
patterns of expression of P-gp1a and P-gp1b reflect differences in
function related to steroid transport, it is important to show
directly that the two proteins are functionally distinct. Some indi-
cations of differences in the biochemical properties of the P-gp1a
and P-gp1b isoforms have been reported: (i) lower progesterone
concentrations are required to inhibit transport by P-gp1b than by
P-gp1a (Yang et al, 1990); (ii) P-gp1a and P-gp1b differ in their
ability to confer cellular resistance to several drugs, including
colchicine and actinomycin D (Devault and Gros, 1990; Yang et
al, 1990; Kajiji et al, 1993; Tang-Wai et al, 1995); (iii) a variety of
P-gp modulators were reported to exhibit isoform-specific differ-
ences in their capacity to reverse vinblastine resistance (Tang-Wai
et al, 1995). However, these are indirect tests of substrate
specificity and do not provide direct information on steroid-P-gp
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confirmed it is important to demonstrate that the two murine P-gp
isoforms have different substrate interaction profiles.
In this study we have assayed directly the interaction of drugs
with the two mouse isoforms. Equilibrium binding assays were
used to assess substrate affinity, association kinetics and the
potency of a range of modulators in displacing bound substrate.
The drug binding characteristics of the two mouse isoforms were
shown to be very similar. In particular, no differences in response
to the modulator progesterone were apparent. These findings
suggest that the different patterns of expression of the two P-gp
isoforms are more likely to reflect an alternative function than
differences in their ability to respond to progesterone. As P-gp1a
and P-gp1b have previously been shown to differ in their abilities
to modulate activation of cell-swelling activated chloride currents
(Valverde et al, 1996), the possibility that this difference may
account for the duplication of isoforms is discussed.
METHODS
Chemicals
[3H]vinblastine sulphate (13.5 Ci mmol–1) and [3H]progesterone
(95 Ci mmol–1) were purchased from Amersham plc (UK).
Vinblastine sulphate, progesterone, nicardipine and verapamil
were obtained from Sigma Chemicals. CP100-356 was a generous
gift from Pfizer. The monoclonal antibody against P-gp (C219)
was purchased from Centocor Diagnostics. Ham’s F12 medium
was from Gibco. All other tissue culture reagents were provided
by the ICRF Clare Hall Laboratory.
Cell culture
Chinese hamster LR73 ovary cells, and their transfected drug-
resistant derivatives overexpressing either mdr1a (LR73-1a) or
mdr1b (LR73-1b) cDNAs were a kind gift from Dr P Gros
(Montreal). Cells were grown as described previously (Devault
and Gros, 1990). Drug-resistant lines were maintained in
50 ng ml–1 vinblastine sulphate which is sufficient to prevent
re-emergence of drug-sensitive cells (EC50 = 10 ng ml–1) but
significantly less than the maximal resistance level of the cells
(EC50 = 200–250 ng ml–1).
Plasma membrane isolation
Plasma membrane fractions were isolated according to previously
published methods (Lever, 1977). Briefly, 1 ´ 109 cells were
grown to confluence, harvested, washed and re-suspended in ice-
cold 50 mM Tris–HCl buffer pH 7.4, containing the protease
inhibitors phenylmethylsulphonyl fluoride (PMSF; 1 mM), EDTA
(1 mM) and benzamidine (1 mM). The cells were disrupted by
nitrogen cavitation (1500 p.s.i.; 2 ´ 15 min) and the membrane
fraction isolated by sucrose (35% w/v) density centrifugation.
Membranes were resuspended and stored in buffer containing
0.01 M Tris–HCl, pH 7.4 and 0.25 M sucrose at –80°C.
P-glycoprotein detection
The amount of P-gp in LR73, LR73-1a and LR73-1b membranes
was assessed by Western immunoblot analysis, based on published
methods (Towbin et al, 1979). Membranes were solubilized in 1%
sodium dodecyl sulphate (SDS) and the protein concentration
assayed with a modified Lowry assay (detergent-compatible
Biorad kit) using bovine serum albumin as a standard. Proteins
were electrophoretically separated on 7.5% SDS-polyacrylamide
gels and transferred onto nitrocellulose membranes (Hybond;
ECL). Membranes were incubated sequentially with the anti-P-gp
monoclonal antibody C219, and horseradish-peroxidase (HRP)-
linked secondary antibody and proteins detected by chemilumines-
cence. Lanes of serially-diluted total membrane protein (1–50 mg)
were quantitated for P-gp by densitometry.
Equilibrium binding of [3H]vinblastine
Equilibrium drug binding to plasma membranes was assayed using
a rapid filtration method, as described previously (Ferry et al,
1992). Membranes (50 mg) were incubated with a range of
[3H]vinblastine concentrations (0.1–100 nM) in buffer A (50 mM
Tris–HCl, pH 7.4) in a total assay volume of 0.2 ml for 120 min in
the dark. Three millilitres of ice-cold buffer B (20 mM Tris–HCl,
20 mM magnesium chloride pH 7.4) were then added to the
samples, and bound and free drug separated by suction through
Whatman GF/F and 0.2 mm nitrocellulose filters (pre-wetted with
0.1% bovine serum albumin (BSA) in buffer A) using a Millipore
multichannel filtration manifold. Filters were washed twice with
3 ml ice-cold buffer B, and retained radioactivity quantitated by
liquid scintillation counting. All results were corrected for non-
specific binding which was defined as the amount of [3H]vin-
blastine bound in the presence of an excess (3 mM) of unlabelled
vinblastine.
Drug displacement assays employed 60 mg or 100 mg of total
membrane protein for LR73-1a or LR73-1b membranes, respec-
tively, and 15–20 nM [3H]vinblastine in a total volume of 0.25 ml.
The concentrations of unlabelled drugs used are indicated in the
figure legends. When progesterone or nicardipine were the
competing drugs, dimethylsulphoxide (DMSO) was used as
solvent to maintain solubility. Since [3H]vinblastine binding is
sensitive to DMSO, with an EC50 of 2.5% (v/v), the assay volume
for these drugs was increased to 1 ml, and 2 ml of the DMSO/drug
solution used, reducing the final concentration of DMSO 0.2%
(v/v). Vinblastine binding in the presence of each competing drug
was corrected for the non-specific binding component (as defined
above).
To measure the association kinetics of [3H]vinblastine binding
to P-gp, assays were carried out in the presence of 15–20 nM
[3H]vinblastine in a volume of 0.25 ml. Reactions were started by
the addition of membranes (60–100 mg protein) followed by incu-
bation for various times over a 180-min period prior to filtration.
Binding to membranes was determined at each time point in the
presence or absence of 3 mM vinblastine.
Data analysis
Saturation binding curves for [3H]vinblastine were analysed using
the Langmuir Isotherm:
BO = {(Bmax *F)/(Kd + F)}
where Bmax = maximum density of binding sites (pmol mg–1)
Kd = dissociation constant (nM)
F = concentration of free [3H]vinblastine (nM).
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binding from P-gp was analysed by non-linear least squares
regression using the general dose–response equation (De Lean
et al, 1978) defined as:
Y = {(a–b)/(1+{x/c}d)} + b
where x = concentration of unlabelled drug (M)
a = maximum amount of [3H]vinblastine bound
b = minimum amount of [3H]vinblastine bound
d = slope factor
c = IC50 concentration (M).
IC50 values generated using this analysis were then used to
calculate Ki values from the Cheng and Prusoff equation (Cheng
and Prusoff, 1973). The Ki value is a measure of the inhibition
constant for given drug whereas the IC50 value varies with both the
[3H]vinblastine concentration and the amount of protein. The Ki
value is defined below.
Ki = IC50/ (1+[L]/Kd)
where IC50 = concentration of drug required to inhibit 50% of
the maximal binding of [3H]vinblastine (M)
L = concentration of [3H]vinblastine used (M)
Kd= dissociation constant for [3H]vinblastine binding (nM).
The association of [3H]vinblastine with P-gp was modelled to
the equation describing a second-order reversible reaction:
where P = P-glycoprotein
V = [3H]vinblastine
k+1 = association rate constant (min–1 nM–1)
k–1 = dissociation rate constant (min–1).
The differential of this equation (see below) was fitted to the
association data and the kinetic constants derived.
All binding data were analysed by Kaleidagraph (Abelbeck
Software). For all assays, means from n experiments are given
with standard errors of the mean (s.e.m.). Statistical comparisons
were made with the Student’s t-test and a P-value of < 0.05 defined
as statistically significant.
RESULTS
Expression of P-gp in LR73 cell lines
The LR73-1a and LR73-1b cell lines used in this study were
derived from Chinese hamster ovary LR73 cells, stably transfected
with the murine mdr1a or mdr1b genes respectively. In order to
compare the levels of P-gp expressed in each cell line, plasma
membranes were prepared, proteins (0.5–12 mg) separated by
SDS-PAGE and P-gp detected by Western blotting (Figure 1).
P-gp in membranes from LR73-1a and LR73-1b membranes ran as
a diffuse band of 160–180 kDa. There was no detectable P-gp in
the parental cell line, LR73 (data not shown). The slight difference
in mobility between Pgp1a and Pgp1b is presumed due to the
differential glycosylation between the two isoforms and has also
been previously described (Valverde et al, 1996). The monoclonal
antibody used, C219, has previously been demonstrated to detect
rodent P-gp irrespective of the isoform (Georges et al, 1990).
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Figure 1 Western immunoblot of membrane protein from the LR73-la and
LR73-1b cell lines. Membrane protein (0.5–12 mg) was loaded onto 8% SDS-
polyacrylamide gels and electrophoresed as described in Materials and
Methods. The proteins were then transferred to nitrocellulose membranes
and probed with the anti-Pgp monoclonal antibody C219
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Figure 2 Saturation isotherm of [3H]vinblastine binding to membranes from
the P-gp expressing cell lines LR73-1a (A) and LR73-1b (B). Membranes
(60–100 mg protein) were incubated with [3H]vinblastine (0–100 nM) for
120 min at 20°C, and bound and free ligand separated by rapid filtration.
Total (l), and non-specific binding (l l) was determined in the absence or
presence of 3-mM unlabelled vinblastine respectively. The specific binding
data (n) were obtained form a single representative experiment and
parameters, obtained from curve fitting as described in Materials and
Methods, were: Kd = 41 ± 19 nM, Bmax = 36 ± 8 pmol mg–1 for P-gp1a;
and Kd = 17 ± 9n M, Bmax = 8.6 ± 1.4 pmol mg–1 for P-gp1bQuantitation of the amount of P-gp in each band by densitometry
revealed that the content of P-gp in LR73-1a membranes was
approximately twice (1.8 ± 0.2-fold) that of the LR73-1b
membranes.
[3H]Vinblastine binding to LR73-1a and LR73-1b
membranes
[3H]Vinblastine (0–100 nM) was shown to bind to membranes
from both LR73-1a and LR73-1b cells in a specific fashion and the
specific component of total binding displayed saturability (Figure
2). Non-specific binding of [3H]vinblastine accounted for approxi-
mately 20% of the total binding. In contrast, [3H]vinblastine did
not bind specifically to the LR73 membranes that do not express
P-gp (data not shown). These assays were carried out in hypotonic
conditions in order to prevent the formation of membrane vesicles,
and the accumulation of [3H]vinblastine within such vesicles,
which would give an overestimate of the binding capacity. The
density of specific binding sites (Bmax) on the LR73-1a membranes
(24.5  ± 2.9 pmol mg–1) was approximately twice that for the
LR73-1b membranes (14.1 ± 2.9 pmol mg–1). Since the data from
the Western blots (see above) indicated that there was about 1.8
times the amount of P-gp in the LR73-1a membranes compared
with the LR73-1b membranes, it appears that P-gp1a and P-gp1b
have the same density of vinblastine-binding sites. The fraction of
total membrane protein which P-gp represents can be estimated
from the Bmax values, assuming that 1 mole of P-gp binds 1 mole of
[3H]vinblastine. The values obtained were 0.42% and 0.25% of
total membrane protein for LR73-1a and LR73-1b membranes
respectively. The affinity of [3H]vinblastine binding was similar
for LR73-1a (Kd = 32.9 ± 4.9 nM) and LR73-1b (30.7 ± 7.6 nM)
membranes, indicating similar drug interaction sites on the two
isoforms. Direct comparison of the binding characteristics of
[3H]progesterone to P-gp was not possible due to (i) the poor
affinity, low specific binding of this compound and (ii) the high
non-specific component of total binding which was indicative of
the hydrophobicity of this compound (data not shown).
Association kinetics for [3H]vinblastine binding to
LR73-1a and LR73-1b membranes
The data above showed no difference in binding site properties
between the P-gp1a and P-gp1b isoforms at equilibrium.
Consequently, the rate at which [3H]vinblastine associates with
P-gp in LR73-1a and LR73-1b membranes was assessed. The
amount of [3H]vinblastine bound to the membranes as a function
of time is shown in Figure 3. Analysis of these data generated rate
constants (k+1) of 0.002 ± 0.0005 and 0.002 ± 0.0006 min–1 nM–1
for LR73-1a and LR73-1b membranes respectively. Similarly the
rate constants of [3H]vinblastine dissociation (derived from Figure
3) from P-gp in LR73-1a (0.07 ± 0.02 min–1) and LR73-1b (0.11 ±
0.02 min–1) membranes were not significantly different. Therefore,
no difference in the kinetics of [3H]vinblastine binding to P-gp1a
and P-gp1b, could be detected. The dissociation constant (Kd) for
the formation of a drug–receptor complex is defined as k–1/k+1.
Estimates of dissociation constants, using the kinetic data, were
35 nM and 55 nM for the P-gp1a and P-gp1b isoforms respectively,
in reasonable agreement with the experimentally derived value
at equilibrium.
Displacement of [3H]vinblastine binding by
pharmacological agents
To further characterize the binding properties of the mouse P-gp
isoforms, particularly the interaction of drugs at the vinblastine-
binding site, several classes of displacing agent were used. The
high affinity ligands, CP100-356 and nicardipine, the well-charac-
terized MDR reversal agent verapamil, and the steroid hormone
progesterone, were studied for their ability to displace specific
[3H]vinblastine binding from P-gp (Figure 4).
The order of potency for displacing vinblastine binding was
CP100-356 > nicardipine > verapamil > progesterone. The
diaminoquinazoline, CP100-356, is clearly a high affinity ligand
for P-gp, with Ki values of 58 ± 2n M and 94 ± 21 nM for the
P-gp1a and P-gp1b isoforms respectively. Nicardipine, a 1,4-dihy-
dropyridine, which binds to a distinct site allosterically-linked
to the vinblastine site (Malkhandi et al, 1994; Martin et al,
1997), displaced [3H]-vinblastine binding to the P-gp1a isoform
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British Journal of Cancer (1999) 81(5), 783–789 © 1999 Cancer Research Campaign
2.5
2.0
1.5
1.0
0.5
0.0
A
B
o
u
n
d
 
[
3
H
]
v
i
n
b
l
a
s
t
i
n
e
 
(
n
M
)
0 30 60 90 120 150 180
Time (min)
3.5
3.0
2.5
2.0
1.5
B
o
u
n
d
 
[
3
H
]
v
i
n
b
l
a
s
t
i
n
e
 
(
n
M
)
B
0 30 60 90 120 150 180
Time (min)
Figure 3 Association kinetics of [3H]vinblastine binding to membranes from
the P-gp-expressing cell lines LR73-1a (A) and LR73-1b (B). Membranes
(60–100 mg) were incubated with [3H]vinblastine (15–20 nM) for the time
indicated prior to filtration. Non-specific binding (in the presence of 3 mM
unlabelled vinblastine) was subtracted from total binding and a single
representative experiment is shown. The association rate constants were
0.002 ± 0.0005 and 0.002 ± 0.0006 min–1 nM–1 for LR73-1a and LR73-1b
membranes respectively(Ki = 128 ± 20 nM) with approximately twice the affinity observed
for P-gp1b-containing membranes (Ki = 239 ± 48 nM; P < 0.05). In
contrast to CP100-356, progesterone was found to have a low and
almost identical affinity for both isoforms (Ki = 1.9 ± 0.3 mM and
1.8  ± 0.2 mM for P-gp1a and P-gp1b respectively). Verapamil
displayed a threefold higher affinity for P-gp1a compared with
P-gp1b (Ki = 1200 ± 200 nM and 3000 ± 500 nM; n = 4), a modest
difference, but one which is statistically significant at the 2% level
(P < 0.02).
In summary, the vinblastine binding site(s) on P-gp1a and
P-gp1b are equivalent in terms of affinity for substrate and the
kinetics of its association/dissociation. The only pharmacological
differences observed were small differences in the ability of
CP100-356 and verapamil to displace vinblastine from its binding
site, perhaps indicating small differences in its structure.
DISCUSSION
Despite their strong sequence similarity, the complementary
patterns of tissue-specific expression suggest that the mouse
isoforms of P-gp may be functionally distinct (Arceci et al, 1988;
Croop et al, 1989; Piekarz et al, 1993; Schinkel et al, 1994). In
particular, the expression patterns of the P-gp1b isoform suggest it
may play a specific role in steroid transport (Altuvia et al, 1993).
Consistent with these ideas, several studies suggest that cells
expressing the P-gp1a and P-gp1b isoforms differ in their resis-
tance to certain drugs (Yang et al, 1990; Kajiji et al, 1993; Tang-
Wai et al, 1995). However, such cytotoxicity assays provide an
indirect assay for drug transport, and differences in cytotoxicity
may be caused by factors other than the transport properties of
P-gp itself. Thus, in this study we directly assayed the interaction
of a variety of compounds, including progesterone, with the
murine P-gp1a and P-gp1b isoforms.
No difference could be detected in the affinity or binding
capacity, at equilibrium, of the two isoforms towards the vinca
alkaloid vinblastine. Similarly, using kinetic techniques, the rate at
which vinblastine associates with the drug binding site was iden-
tical for both P-gp1a and P-gp1b. However, a previous manuscript
has suggested that P-gp1a is a more ‘efficient’ [3H]vinblastine
transporter than Pgp1b (Yang et al, 1990). This difference between
binding and transport data suggests that the isoforms differ in
substrate handling at a point subsequent to the initial binding
interaction. It is possible that coupling between binding and ATP
hydrolysis, which is required for transport, or perhaps a step in the
translocation pathway differs between the P-gp1a and P-gp1b
isoforms. Both studies indicate similar binding affinity and
capacity of the isoforms towards P-gp; however, the data obtained
from Yang et al (1990) suggested that the P-gp1a isoform contains
a second [3H]vinblastine-binding site. Our data show no evidence
for more than one vinblastine-binding site on either P-gp isoform.
The presence of two binding sites was derived following linear
transformation of the binding data using the Scatchard technique.
This type of analysis has been questioned and proved statistically
invalid (Burgisser, 1984; Kenakin, 1997). Using the now preferred
technique of non-linear regression we were unable to detect the
presence of multiple binding sites on P-gp for vinblastine.
A further approach to characterizing drug binding by the two
isoforms of P-gp was the use of agents to displace vinblastine
binding. Several lines of evidence measuring transport, binding
and ATPase activity of P-gp have pointed to the presence of
multiple drug interaction sites (Ferry et al, 1992, 1995; Spoelstra et
al, 1992; Malkhandi et al, 1994; Ayesh et al, 1996; Orlowski et al,
1996; Martin et al, 1997). CP100-356 is a diaminoquinazoline and
amongst the most potent MDR-modulating agents reported (Kajiji
et al, 1994), hence providing specificity and selectivity of binding
displacement. The modest difference in the affinity of P-gp1a
and P-gp1b for CP100-356, estimated by its ability to displace
vinblastine binding, and similar modest differences for verapamil,
are unlikely to account for the duplication of the two drug trans-
porting P-gp isoforms in mouse. Nicardipine, a 1,4-dihydropyri-
dine, in contrast to CP100-356 and verapamil, increases the
dissociation rate for vinblastine implying that it interacts with a
distinct but allosterically-linked binding site. The similar potency
with which nicardipine displaced vinblastine binding from P-gp1a
and P-gp1b shows that the two isoforms are unlikely to differ
significantly in this second binding site or in communication
between the two allosterically-linked sites.
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Figure 4 The effects of CP100-356 (l), nicardipine (l l), verapamil (n) and
progesterone (n n) on [3H]vinblastine binding to membranes from the
P-gp-expressing cell lines LR73-1a (A) and LR73-1b (B). Drugs were added
at the concentrations indicated in the presence of [3H]vinblastine (15–20 nM),
and equilibrated for 120 min prior to filtration. Non-specific binding was
determined in the presence of 3-mM unlabelled vinblastine. The values (mean
± s.e.m.) were obtained from 3–5 independent membrane preparationsBased on tissue-specific patterns of expression, and a proges-
terone response element in the mdr1b promoter region, a physio-
logical role in steroid transport has been suggested for P-gp1b.
However, we were unable to demonstrate any difference in the
ability of progesterone to affect vinblastine binding to P-gp1a and
P-gp1b. Previous reports, using a range of less direct assay tech-
niques, also failed consistently to distinguish between the two
mouse isoforms in terms of steroid binding or transport properties
(Ueda et al, 1992; Barnes et al, 1996). Thus, the present data
suggest that differences in the ability to transport progesterone are
unlikely to account for the duplication giving rise to P-gp1a and
P-gp1b. In addition, the Ki value for progesterone binding to
P-gp determined here demonstrates a sufficiently poor affinity that
progesterone is unlikely to be a physiological substrate in vivo. It
seems more likely that progesterone regulates the relative cellular
expression levels of the two isoforms of P-gp.
In conclusion, we have found no significant differences between
the P-gp1a and P-gp1b isoforms in the nature of drug binding sites
or communication between allosterically linked regulatory sites.
Therefore, if biochemical differences exist between the isoforms
they must be at a later step in transport such as the translocation
step or linkage between drug binding and ATP hydrolysis. The
possibility that the gene duplication is of no functional signifi-
cance seems unlikely given its conservation in all rodents exam-
ined. Alternatively, the duplication may reflect a function for P-gp
distinct from its drug transport properties. In this regard, P-gp has
been shown to modulate the activation of cell swelling-activated
chloride currents, an activity distinct and separable from its
function as a drug transporter (Gill et al, 1992; Hardy et al, 1995;
Valverde et al, 1996). Interestingly, the two murine isoforms of
P-gp differ in their ability to modulate channel activity; the P-gp1a
isoform, like human P-gp increases the rate of activation of
chloride currents while, in contrast, P-gp1b appears to have no
effect (Valverde et al, 1996).
The P-gp1a and P-gp1b isoforms appear to differ with respect
to: (i) modulating cell volume activated chloride currents
(Valverde et al, 1996), (ii) cellular efflux of [3H]vinblastine (Yang
et al, 1990) and (iii) tissue distribution profiles (Croop et al, 1989).
However, in the present manuscript we have detailed that the
initial drug binding event/interaction between the two isoforms
and several substrates is identical. Combined these pieces of
evidence suggest that the presence of multiple isoforms of P-gp
allows subtle quantitative and qualitative regulation of its respec-
tive cellular activity.
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